Article
Horizon Discovery Expands Screening Services
Author(s):
Horizon Discovery has announced that it has expanded its cell-based clustered regularly interspaced short palindromic repeats (CRISPR) screening services to include primary human B cells, which complements the T cell screening service.
Horizon Discovery has announced, in an April 3, 2020 press release, that it has expanded its cell-based clustered regularly interspaced short palindromic repeats (CRISPR) screening services to include primary human B cells, which complements the T cell screening service.
The new arrayed CRISPR knockout screening service for B cells will allow researchers the ability to identify genes that affect the function of B cells and examine how this might impact other types of immune cells. These capabilities are particularly aimed at use in infectious diseases, cancer, and auto-immune disorders, such as COVID-19, Burkitt’s lymphoma, and multiple sclerosis, respectively.
“The interest in harnessing the immune system for effective therapies continues to grow, with the global cell therapy market predicted to reach $8.21 billion by 2025 [according to market research],” said Terry Pizzie, CEO, Horizon Discovery, in the press release. “Expanding our services to encompass screening of both primary T and B cells is another example of our commitment to apply decades of gene editing experience in support of drug discovery and development for the treatment of human disease.”
Source: Horizon Discovery
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
